[Efficacy and tolerability of gabapentin in the treatment of patients with neuropathic pain. Results of an observational study involving 5620 patients].
Junker
U
U
Abt. Spezielle Schmerztherapie und Palliativmedizin Sana Klinikum Remscheid GmbH Hans-Potyka-Str. 28, D-42827 Remscheid.
Brunnmüller
U
U
D000085:Acetates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000588:Amines; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D003929:Diabetic Neuropathies / Q000188:drug therapy; D000077206:Gabapentin; D006562:Herpes Zoster / Q000150:complications; D006801:Humans; D009437:Neuralgia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D017060:Patient Satisfaction; D013997:Time Factors; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000700:Analgesics; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin